Prevailing theories recognize that SGLT2 is not expressed in cardiomyocytes; therefore, the beneficial effects in HF must be off target (not mediated by SGLT2) or due to extracardiac SGLT2 inhibition (e.g., in the kidney). Here, SLC5A2 is linked to hydrops fetalis.